Company History: Transforming Prostate Cancer Diagnosis and Treatment

Triopsy™ Medical, Inc.™ emerged under the guidance of renowned experts in the field of urology. These key opinion leaders identified the pressing need for refining prostate cancer diagnosis and embarked on a mission to elevate the standard of care in this critical domain. The driving force behind Triopsy™ was the desire to bridge the gap between overtreating and undertreating prostate cancer, delivering a precision tool to enable physicians to diagnose patients more accurately, aligning treatment with their precise disease state.

Prostate cancer diagnosis frequently relies on transrectal ultrasound-guided biopsies (TRUS), which carry a substantial risk of misclassification and overdiagnosis, often resulting in unnecessary treatments that can harbor debilitating side effects. Moreover, conventional biopsy devices currently available offer limited control over sample length resulting in a small specimen that is not representative of the total prostate and specimen fragmentation, thereby providing limited representative tissue resulting in diminishing diagnostic accuracy. This compelling challenge spurred the inception of Triopsy™, a company committed to revolutionizing prostate cancer diagnosis and care.

Triopsy™ introduced a groundbreaking system comprising a fully adjustable 5.5cm biopsy needle, an adaptable and reusable biopsy actuator, and an Integrated Pathology System (IPS). These innovations aim to enhance the precision of prostate cancer diagnosis and reduce the risk of over or underdiagnosing patients. The Triopsy™ System empowers urologists to obtain longer, unfragmented tissue samples, significantly elevating the accuracy of locating and identifying prostate cancer lesions.

A pivotal advancement is the Triopsy™ Needle, capable of capturing a single, unfragmented core sample up to 5.5cm in length whereas conventional biopsy needles provide capability for a maximum of 2cm sample. This addresses the constraints of conventional biopsy needles, which frequently yield shorter and often fragmented specimens. These innovations include:

  • Longer, 5.5cm needle sampling bed allows for full length of prostate sample collection in a single event;

  • Gripping ridges on the needle bed to hold the soft tissue in place while the cannula performs the cut, alleviating fragmentation;

  • Trocar point allowing for 'straight-on’ targeting of sample area rather than the traditional beveled point that requires an ‘aim-high’ targeting estimation.

The innovations contained within Triopsy’s Needle design have been recognized with issued patents.

Furthermore, the Triopsy™ Biopsy Actuator offers physicians the capability to adjust the length of the biopsy core from 1.7 to 5.5cm, thus enhancing control and precision throughout the entire procedure.

The Integrated Pathology System (IPS) represents a pioneering solution for the secure handling and electronic tracking of the full length tissue samples produced by Triopsy’s Needle. Its self-sealing, adhesive design mitigates biohazard risks to medical personnel and reduces the potential for specimen handling errors, safeguarding sample integrity from the urologist's office to the pathology laboratory and making its use a benefit for all needle biopsy samples, not just those from Triopsy’s needle.

Triopsy™ envisions a paradigm shift in the standard of care for prostate biopsies. In standard TRUS biopsies, our patented Needle significantly reduces the systematic error associated with the procedure by allowing for the sampling of the anterior zone of the prostate, where up to 25% of index lesions are frequently missed by conventional biopsy needles due to the shorter needle sampling bed. In transperineal approaches, our adjustable Actuator grants physicians the ability to customize the length of the biopsy, spanning from the apex to the base of the prostate, allowing for a single, comprehensive sampling along the entire prostate length, something current biopsy needles are incapable of providing. By enhancing core length and specimen integrity, Triopsy™ strives to curtail the need for redundant biopsies and offer timelier, more effective treatment options for prostate cancer patients.

Triopsy™ Medical™ was established to confront the pressing need for a more precise prostate cancer diagnosis. Our pioneering Triopsy™ System, featuring the Biopsy Actuator, Needle, and IPS, is dedicated to enhancing biopsy precision, sampling prostate areas that frequently elude diagnosis, and elevating diagnostic accuracy for each patient in the battle against prostate cancer.

For more information, please contact

Brad J. Buscher
Executive Chairman of the Board
bbuscher@triopsy.com